Emerging agents for boron neutron capture therapy: Biomolecular carriers paving the way for precision radiotherapy

Abstract

Boron neutron capture therapy (BNCT) is an emerging targeted radiotherapy technology that enables precise eradication of tumor cells. The development of efficient boron carriers is crucial for the advancement of BNCT technology. Notably, biomolecular carriers currently represent the only class of drug carriers that has achieved market approval (e.g., boronophenylalanine [BPA] in Japan), underscoring their pivotal role in clinical applications. Their outstanding biocompatibility, high payload capacity, and tumor-targeting capabilities align closely with the stringent requirements of BNCT drug delivery. For instance, amino acid-based carriers (such as BPA) utilize L-type amino acid transporter 1 (LAT1) for tumor-specific accumulation; nucleoside prodrugs are activated by thymidine kinase 1 (TK1) and incorporated into tumor DNA; carbohydrate-based carriers improve solubility and targeting through glucose transporters (GLUTs); peptide carriers facilitate cellular uptake via receptor-mediated endocytosis or cell-penetrating peptides; and liposomes leverage the enhanced permeability and retention (EPR) effect together with active-targeting modifications for enhanced tumor delivery. Nevertheless, delivering ultrahigh doses of boron remains a major challenge. Biomacromolecules, particularly albumin-based systems, have garnered increasing attention because of their excellent biosafety and high boron-loading potential, offering promising avenues for overcoming dose delivery barriers in BNCT. This review systematically summarizes the recent advances in biomolecular carriers for BNCT and highlights emerging applications of protein-based boron carriers, addressing a notable gap in the comprehensive review of biomolecular strategies within the BNCT drug delivery field.

Keywords

Biomolecular Carriers / Boron Neutron Capture Therapy / Precision Radiotherapy

References

[1] Donya H, Alzahrani NM, Abdulsalam A, et al. Boron neutron capture therapy: a promising radiation treatment modality. Radiat Environ Biophys. 2025; 64(3): 339-353.

[2] He H, Li J, Jiang P, et al. The basis and advances in clinical application of boron neutron capture therapy. Radiat Oncol. 2021; 16(1): 216.

[3] Ali F, Hosmane SN, Zhu Y. Boron Chemistry for Medical Applications. Molecules. 2020; 25(4):828.

[4] Hosmane NS, Maguire JA, Zhu Y, Takagaki M. Boron and Gadolinium Neutron Capture Therapy for Cancer Treatment. World Scientific Publishing; 2012.

[5] Li XL, Liu ZJ, Liu KJ, et al. Advances in Clinical Trials of Boron Neutron Capture Therapy. Research. 2025; 9:0988.

[6] Chadwick J. Possible existence of a neutron. Nature, 1932; 129(3252): 312.

[7] Locher GL. Biological effects and therapeutic possibilities of neutrons. Am J Roentgenol. 1936; 36: 1-13.

[8] Farr LE, Sweet WH, Locksley HB, et al. Neutron capture therapy of gliomas using boron. Trans Am Neurol Assoc. 1954; 13: 110-113.

[9] Farr LE, Sweet WH, Robertson JS, et al. Neutron capture therapy with boron in the treatment of glioblastoma multiforme. Am J Roentgenol Radium Ther Nucl Med. 1954; 71: 279-293.

[10] Goodwin JT, Farr LE, Sweet WH, et al. Pathological study of eight patients with glioblastoma multiforme treated by neutron-capture therapy using boron 10. Cancer. 1955; 8(3): 601-615.

[11] Jin WH, Seldon C, Butkus M, et al. A review of boron neutron capture therapy: its history and current challenges. Int J Particle Ther. 2022; 9(1): 71-82.

[12] Hatanaka H. Clinical results of boron neutron capture therapy. Basic Life Sci. 1990; 54: 15-21.

[13] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-996.

[14] Mishima Y, Ichihashi M, Hatta S, et al. First human clinical trial of melanoma neutron capture: diagnosis and therapy. Strahlenther Onkol. 1989; 165(2-3): 251-254.

[15] Yoshino K, Suzuki A, Mori Y, et al. Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides. Strahlenther Onkol. 1989; 165(2-3): 127-129.

[16] Wittig A, Sauerwein WA, Coderre JA. Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiat Res. 2000; 153(2): 173-180. 0173:motopb]2.0.co;2

[17] Kato I, Ono K, Sakurai Y, et al. Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot. 2004; 61(5): 1069-1073.

[18] Shirakawa M, Zasshi Y. Chasing New Cancer Treatments: Current Status and Future Development of Boron Neutron Capture Therapy. J Pharm Soc Jpn. 2024; 144(9): 871-876.

[19] Chen C, Wang C, Zhang L, et al. Systemic Immunity Triggered by Boron Neutron Capture Therapy via Manganese-Borate Complex. Mater Today Bio. 2026; 37:102904.

[20] Li XL, Liu ZJ, Liu KJ, et al. Advances in clinical trials of boron neutron capture therapy. Res (Wash DC). 2026; 9:0988.

[21] Snyder HR, Reedy AJ, Lennarz WJ. Synthesis of aromatic boronic acids. Aldehydo boronic acids and a boronic acid analog of tyrosine. J Am Chem Soc. 1958; 80: 835-838.

[22] Brattsev V, Stanko V. β-(O-baranyl)alanine. Zh Obshch Khim. 1969; 39: 1175-1176.

[23] Kirihata M, Morimoto T, Mizuta T, Ichimoto I. Tumor-targeted boron-containing amino acid. Part II. Synthesis of p-boronophenylserine, a new boron-containing amino acid for boron neutron capture therapy. Biosci Biotechnol Biochem. 1995; 59(12): 2317-2318.

[24] Shull BK, Spielvogel DE, Head G, et al. Studies on the structure of the complex of the boron neutron capture therapy drug, L-p-boronophenylalanine, with fructose and related carbohydrates: chemical and 13C NMR evidence for the beta-D-fructofuranose 2,3,6-(p-phenylalanylorthoboronate) structure. J Pharm Sci. 2000; 89(2): 215-222.

[25] Gruzdev DA, Telegina AA, Levit GL, et al. Synthesis of charge-compensated nido-carboranyl derivatives of sulfur-containing amino acids and biotin. J Org Chem. 2023; 88(19): 14022-14032.

[26] Järvinen J, Pulkkinen H, Rautio J, Timonen JM. Amino acid-based boron carriers in boron neutron capture therapy (BNCT). Pharmaceutics. 2023; 15(12):2663.

[27] Raitano A, Martin T, Zhang C, et al. Boronotyrosine, a borylated amino acid mimetic with enhanced solubility, tumor boron delivery, and retention for the re-emerging boron neutron capture therapy field. J Med Chem. 2023; 66(19): 13809-13820.

[28] Isohashi K, Kanai Y, Aihara T, et al. Exploration of the threshold SUV for diagnosis of malignancy using 18F-FBPA PET/CT. Eur J Hybrid Imaging. 2022; 6(1): 35.

[29] Hattori Y, Ishimura M, Ohta Y, et al. Detection of boronic acid derivatives in cells using a fluorescent sensor. Org Biomol Chem. 2015; 13(25): 6927-6930.

[30] Li SM, Bi X, Yang F, et al. Dual-microRNA triggered and DNA-programmed nanomachine for subtype-based detection and tailored treatment of breast cancer cells. Biomed Anal. 2024; 1(1): 46-53.

[31] Parikh D, Shah M. A comprehensive study on epigenetic signatures to monitor disease progression and the response to therapy in breast cancer. Biomed Anal. 2024; 1: 205-217.

[32] Zharkov DO, Yudkina AV, Riesebeck T, et al. Boron-containing nucleosides as tools for boron-neutron capture therapy. Am J Cancer Res. 2021; 11(10): 4668-4682.

[33] Lunato AJ, Wang J, Woollard JE, et al. Synthesis of 5-(carboranylalkylmercapto)-2'-deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2. J Med Chem. 1999; 42(17): 3378-3389.

[34] Al-Madhoun AS, Johnsamuel J, Barth RF, et al. Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. Cancer Res. 2004; 64(17): 6280-6286.

[35] Leśnikowski ZJ, Paradowska E, Olejniczak AB, et al. Towards new boron carriers for boron neutron capture therapy: metallacarboranes and their nucleoside conjugates. Bioorg Med Chem. 2005; 13(13): 4168-4175.

[36] Luvino D, Baraguey C, Smietana M, Vasseur JJ. Borononucleotides: synthesis, and formation of a new reversible boronate internucleosidic linkage. Chem Commun. 2008;(20): 2352-2354.

[37] Kirihata M, Morimoto TT, Ichimoto I. Tumor-targeted boron-containing amino acid. 2. Synthesis of p-boronophenylserine, a new boron-containing amino acid for boron neutron capture therapy. J Agric Chem Soc Jpn. 1995; 59(12): 2317-2318.

[38] Muz B, Azab AK, Confalonieri L, et al. Synthesis, equilibrium, and biological study of a C-7 glucose boronic acid derivative as a potential candidate for boron neutron capture therapy. Bioorg Med Chem. 2022; 59:116659.

[39] Itoh T, Tamura K, Ueda H, et al. Design and synthesis of boron containing monosaccharides by the hydroboration of d-glucal for use in boron neutron capture therapy (BNCT). Bioorg Med Chem. 2018; 26(22): 5922-5933.

[40] Fujimoto T, Teraishi F, Kanehira N, et al. BNCT pancreatic cancer treatment strategy with glucose-conjugated boron drug. Biomaterials. 2024; 309:122605.

[41] Yamana K, Kawasaki R, Kondo K, et al. HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex. Nanoscale Adv. 2023; 5(15): 3857-3861.

[42] Mitusova K, Peltek OO, Karpov TE, et al. Overcoming the blood–brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches. J Nanobiotechnol. 2022; 20(1): 412.

[43] Zhang Z, Wang X, Dai Q, et al. Peptide-functionalized gold nanoparticles for boron neutron capture therapy with the potential to use in Glioblastoma treatment. Pharm Dev Technol. 2024; 29(8): 862–873.

[44] Nakase I, Aoki A, Sakai Y, et al. Antibody-based receptor targeting using an Fc-binding peptide-dodecaborate conjugate and macropinocytosis induction for boron neutron capture therapy. ACS Omega. 2020; 5(36): 22731-22738.

[45] Hoppenz P, Els-Heindl S, Kellert M, et al. A selective carborane-functionalized gastrin-releasing peptide receptor agonist as boron delivery agent for boron neutron capture therapy. J Org Chem. 2020; 85(3): 1446-1457.

[46] Worm DJ, Hoppenz P, Els-Heindl S, et al. Selective neuropeptide Y conjugates with maximized carborane loading as promising boron delivery agents for boron neutron capture therapy. J Med Chem. 2020; 63(5): 2358-2371.

[47] Michiue H, Sakurai Y, Kondo N, et al. The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide. Biomaterials. 2014; 35(10): 3396-3405.

[48] Iguchi Y, Michiue H, Kitamatsu M, et al. Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model. Biomaterials. 2015; 56: 10-17.

[49] Nakase I, Katayama M, Hattori Y, et al. Intracellular target delivery of cell-penetrating peptide-conjugated dodecaborate for boron neutron capture therapy (BNCT). Chem Commun. 2019; 55(93): 13955-13958.

[50] Xiang J, Ma L, Tong J, et al. Boron-peptide conjugates with angiopep-2 for boron neutron capture therapy. Front Med. 2023; 10:1199881.

[51] Kawai K, Nishimura K, Okada S, et al. Cyclic RGD-functionalized closo-dodecaborate albumin conjugates as integrin targeting boron carriers for neutron capture therapy. Mol Pharmaceutics. 2020; 17(10): 3740-3747.

[52] Mishiro K, Imai S, Ematsu Y, et al. RGD peptide-conjugated dodecaborate with the Ga-DOTA complex: a preliminary study for the development of theranostic agents for boron neutron capture therapy and its companion diagnostics. J Med Chem. 2022; 65(24): 16741-16753.

[53] Meher N, Seo K, Wang S, et al. Synthesis and preliminary biological assessment of carborane-loaded theranostic nanoparticles to target prostate-specific membrane antigen. ACS Appl Mater Interfaces. 2021; 13(46): 54739-54752.

[54] Sharma KS, Raju MS, Phapale S, et al. Multimodal applications of zinc gallate-based persistent luminescent nanoparticles in cancer treatment: tumor margining, diagnosis, and boron neutron capture therapy. ACS Appl Bio Mater. 2022; 5(7): 3134-3145.

[55] Isono A, Kanno Y, Uchiro H, Makino K. Polyborane-encapsulated PEGylated liposomes prepared using post-insertion technique for boron neutron capture therapy. J Oleo Sci. 2019; 68(12): 1261-1270.

[56] Liu Y, Wang Y, Wang C, et al. Hijacking self-assembly to establish intracellular functional nanoparticles. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2022; 9(31):e2203027.

[57] Shelly K, Feakes DA, Hawthorne MF, et al. Model studies directed toward the boron neutron-capture therapy of cancer: boron delivery to murine tumors with liposomes. Proc Natl Acad Sci U S A. 1992; 89(19): 9039-9043.

[58] Feakes DA, Shelly K, Hawthorne MF. Selective boron delivery to murine tumors by lipophilic species incorporated in the membranes of unilamellar liposomes. Proc Natl Acad Sci U S A. 1995; 92(5): 1367-1370.

[59] Maitz CA, Khan AA, Kueffer PJ, et al. Validation and comparison of the therapeutic efficacy of boron neutron capture therapy mediated by boron-rich liposomes in multiple murine tumor models. Transl Oncol. 2017; 10(4): 686-692.

[60] Heber EM, Hawthorne MF, Kueffer PJ, et al. Therapeutic efficacy of boron neutron capture therapy mediated by boron-rich liposomes for oral cancer in the hamster cheek pouch model. Proc Natl Acad Sci U S A. 2014; 111(45): 16077-16081.

[61] Yanagie H, Yanagawa M, Morishita Y, et al. Suppression of tumor growth in a rabbit hepatic cancer model by boron neutron capture therapy with liposomal boron delivery systems. In Vivo. 2021; 35(6): 3125-3135.

[62] Lee W, Sarkar S, Ahn H, et al. PEGylated liposome encapsulating nido-carborane showed significant tumor suppression in boron neutron capture therapy (BNCT). Biochem Biophys Res Commun. 2020; 522(3): 669-675.

[63] Takeuchi I, Kanno Y, Uchiro H, Makino K. Polyborane-encapsulated PEGylated liposomes prepared using post-insertion technique for boron neutron capture therapy. J Oleo Sci. 2019; 68(12): 1261-1270.

[64] Kullberg EB, Wei Q, Capala J, et al. EGF-receptor targeted liposomes with boronated acridine: growth inhibition of cultured glioma cells after neutron irradiation. Int J Radiat Biol. 2005; 81(8): 621-629.

[65] Li J, Sun Q, Lu C, et al. Boron encapsulated in a liposome can be used for combinational neutron capture therapy. Nat Commun. 2022; 13(1): 2143.

[66] Kikuchi S, Sato S, Nakamura H. Carrier proteins-based boron delivery to tumor. Appl Radiat Isot. 2020; 157:109011.

[67] Marforio TD, Mattioli EJ, Zerbetto F, Calvaresi M. Exploiting blood transport proteins as carborane supramolecular vehicles for boron neutron capture therapy. Nanomaterials. 2023; 13(11):1770.

[68] Rak J, Jakubek M, Kaplánek R, Matějíček P, Král V. Cobalt bis(dicarbollide) derivatives: solubilization and self-assembly suppression. Eur J Med Chem. 2011; 46(4): 1140-1146.

[69] Julius RL, Farha OK, Chiang J, Perry LJ, Hawthorne MF. Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores. Proc Natl Acad Sci U S A. 2007; 104(12): 4808-4813.

[70] Rak J, Dejlová B, Lampová H, et al. Solubilization and deaggregation of cobalt bis(dicarbollide) derivatives in water by biocompatible excipients. Bioorg Med Chem Lett. 2010; 20(3): 1045-1048.

[71] Rak J, Kaplánek R, Král V. On the solubility and lipophilicity of metallacarborane pharmacophores. Mol Pharmaceutics. 2013; 10(5): 1751-1759.

Rights & permissions

2026 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.